EP1013 and Islet Allograft Survival
Animal study · Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients [1]
In Balb/C donor islet allografts transplanted into chemically diabetic B6 recipients, EP1013 was administered by medium incubation at 100 μmol/l and s.c. dosing at 3 mg/kg. Mean allograft survival was 18.2 days versus 22.8 days in vehicle-treated animals, with no prolongation of survival.
| Endpoint | Reported result | Reference |
|---|---|---|
| islet allograft survival | islet allograft survival EP1013 at 100 μmol/l; 3 mg/kg s.c., days 0–10: mean survival time 18.2 days | [1] |
Conditions shared by the study groups
- Route
- incubated in medium; s.c.
- Treatment course
- Before transplantation; for 2 h; days 0–10
- Vehicle
- DMSO in sterile saline
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| EP1013 100 μmol/l; 3 mg/kg | vehicle-treated animals | no prolongation of islet allograft survival (mean survival time 18.2 days) compared with vehicle-treated animals (mean survival time 22.8 days, P = NS) | [1] |
- EP1013 100 μmol/l; 3 mg/kg
- Model: Balb/C (H-2d) donors and chemically diabetic B6 (H-2b) recipients
Methods and source locations
Compound reported in the paper: EP1013
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S6, S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S27, S28); FIG. 1. legend (S66)
islet allograft survival: islet allograft survival; comparator: vehicle-treated animals — RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S28)
EP1013 100 μmol/l; 3 mg/kg · RESEARCH DESIGNS AND METHODS > Islet transplantation studies. (S7, S8); RESULTS > Combination of EP1013 and CTLA4-Ig results in long-term islet allograft acceptance and operational tolerance. (S28)